The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy
Open accessAbstract
BACKGROUND: Although human mesenchymal stem cells (hMSCs) have been tested in ischemic cardiomyopathy, few studies exist in chronic nonischemic dilated cardiomyopathy (NIDCM). OBJECTIVES: The authors conducted a randomized comparison of safety and efficacy of autologous (auto) versus allogeneic (allo) bone marrow-derived hMSCs in NIDCM. METHODS: Thirty-seven patients were randomized to either allo- or auto-hMSCs in a 1:1 ratio. Patients were recruited between December 2011 and July 2015 at the University of Miami Hospital. Patients received hMSCs (100 million) by transendocardial stem cell injection in 10 left ventricular sites. Treated patients were evaluated at baseline, 30 days, and 3-, 6-, and 12-months for safety (serious adverse events [SAE]), and efficacy endpoints: ejection fraction, Minnesota Living with Heart Failure Questionnaire, 6-min walk test, major adverse cardiac events, and immune biomarkers. RESULTS: There were no 30-day treatment-emergent SAEs. Twelve-month SAE incidence was 28.2% with allo-hMSCs versus 63.5% with auto-hMSCs (p = 0.1004 for the comparison). One allo-hMSC patient developed an elevated (>80) donor-specific calculated panel reactive antibody level. The ejection fraction increased in allo-hMSC patients by 8.0 percentage points (p = 0.004) compared with 5.4 with auto-hMSCs (p = 0.116; allo vs. auto p = 0.4887). The 6-min walk test increased with allo-hMSCs by 37.0 m (p = 0.04), but not auto-hMSCs at 7.3 m (p = 0.71; auto vs. allo p = 0.0168). MLHFQ score decreased in allo-hMSC (p = 0.0022) and auto-hMSC patients (p = 0.463; auto vs. allo p = 0.172). The major adverse cardiac event rate was lower, too, in the allo group (p = 0.0186 vs. auto). Tumor necrosis factor-α decreased (p = 0.0001 for each), to a greater extent with allo-hMSCs versus auto-hMSCs at 6 months (p = 0.05). CONCLUSIONS: These findings demonstrated safety and clinically meaningful efficacy of allo-hMSC versus auto-hMSC in NIDCM patients. Pivotal trials of allo-hMSCs are warranted based on these results. (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy [PoseidonDCM]; NCT01392625).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure
Levine, B., Kalman, J., Mayer, L., Fillit, H. M., & Packer, M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007263230405 · Cited by 2,582 · cited 1×
“Elevated levels of TNF-a, a crucial proinflammatory cytokine, are tied to heart disease progression and are implicated in modulating both cardiac contractility and peripheral resistance (22,23).”
Underlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy
Felker, G. M., Thompson, R. E., Hare, J. M., Hruban, R. H., Clemetson, D. E., Howard, D. L., Baughman, K. L., & Kasper, E. K. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004133421502 · Cited by 1,723
Self-citationLe Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., & Ringdén, O. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00110-3 · Cited by 1,623
Hare, J. M., Traverse, J. H., Henry, T. D., Dib, N., Strumpf, R. K., Schulman, S. P., Gerstenblith, G., DeMaria, A. N., Denktas, A. E., Gammon, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.055 · Cited by 1,350
Self-citationMann, D. L., McMurray, J. J. V., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., Djian, J., Drexler, H., Feldman, A., Kober, L., et al. (2004) · Circulation · doi:10.1161/01.cir.0000124490.27666.b2 · Cited by 1,240
Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine
Murphy, M. B., Moncivais, K., & Caplan, A. I. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.94 · Cited by 1,231
Hare, J. M., Fishman, J. E., Gerstenblith, G., DiFede Velazquez, D. L., Zambrano, J. P., Suncion, V. Y., Tracy, M., Ghersin, E., Johnston, P. V., Brinker, J. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.25321 · Cited by 1,192
Self-citationTranscoronary Transplantation of Progenitor Cells after Myocardial Infarction
Assmus, B., Honold, J., Schächinger, V., Britten, M. B., Fischer-Rasokat, U., Lehmann, R., Teupe, C., Pistorius, K., Martin, H., Abolmaali, N. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051779 · Cited by 1,040
Lund, L. H., Edwards, L. B., Dipchand, A. I., Goldfarb, S., Kucheryavaya, A. Y., Levvey, B. J., Meiser, B., Rossano, J. W., Yusen, R. D., & Stehlik, J. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.08.017 · Cited by 763
Cited by
Mesenchymal stem cell perspective: cell biology to clinical progress
Pittenger, M. F., Discher, D. E., Péault, B. M., Phinney, D. G., Hare, J. M., & Caplan, A. I. (2019) · npj Regenerative Medicine · doi:10.1038/s41536-019-0083-6 · Cited by 2,008
Self-citationMyocarditis and inflammatory cardiomyopathy: current evidence and future directions
Tschöpe, C., Ammirati, E., Bozkurt, B., Caforio, A. L. P., Cooper, L. T., Felix, S. B., Hare, J. M., Heidecker, B., Heymans, S., Hübner, N., et al. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00435-x · Cited by 1,217
Self-citationStem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074
Cardiomyocyte Regeneration: A Consensus Statement
Eschenhagen, T., Bolli, R., Braun, T., Field, L. J., Fleischmann, B. K., Frisén, J., Giacca, M., Hare, J. M., Houser, S., Lee, R. T., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029343 · Cited by 499
Self-citationClinical application of mesenchymal stem cell in regenerative medicine: a narrative review
Margiana, R., Markov, A., Zekiy, A. O., Hamza, M. U., Al-Dabbagh, K. A., Al-Zubaidi, S. H., Hameed, N. M., Ahmad, I., Sivaraman, R., Kzar, H. H., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03054-0 · Cited by 429
Metadata
- Authors
- Hare, J. M., DiFede, D. L., Rieger, A. C., Florea, V., Landin, A. M., El-Khorazaty, J., Khan, A., Mushtaq, M., Lowery, M. H., Byrnes, J. J., Hendel, R. C., Cohen, M. G., Alfonso, C. E., Valasaki, K., Pujol, M. V., Golpanian, S., Ghersin, E., Fishman, J. E., Pattany, P., Gomes, S. A., Delgado, C., Miki, R., Abuzeid, F., Vidro-Casiano, M., Premer, C., Medina, A., Porras, V., Hatzistergos, K. E., Anderson, E., Mendizabal, A., Mitrani, R., & Heldman, A. W.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 69
- Issue
- 5
- Pages
- 526-537
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2549128727
- Cited by
- 355
- References
- 32
- FWCI
- 24.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy. https://app.cochat.ai/papers/10.1016/j.jacc.2016.11.009
- The paper
- Hare, J. M., DiFede, D. L., Rieger, A. C., Florea, V., Landin, A. M., El-Khorazaty, J., Khan, A., Mushtaq, M., Lowery, M. H., Byrnes, J. J., Hendel, R. C., Cohen, M. G., Alfonso, C. E., Valasaki, K., Pujol, M. V., Golpanian, S., Ghersin, E., Fishman, J. E., Pattany, P., . . . Heldman, A. W. (2017). Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2016.11.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
